Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Thalidomide × Dermatologic × Clear all

Phase

Status

Completed 8 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 16 Gastrointestinal 11 Thoracic 6 Lymphoid 5 Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1 NET 1 Genitourinary 1 Endocrine 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

Nivolumab 24 pembrolizumab 18 Ipilimumab 15 Temozolomide 13 toripalimab 9 Cyclophosphamide 9 Biopsy 9 Blood Specimen Collection 8 Dacarbazine 7 camrelizumab 6 Imiquimod 6 trametinib 5 fludarabine 5 dabrafenib 5 atezolizumab 5 aldesleukin 5 Cisplatin 5 Chemotherapy, Adjuvant 5 fludarabine phosphate 4 durvalumab 4 binimetinib 4 apatinib 4 Sorafenib 4 Interleukin-2 4 Injections 4 Gene Expression Profiling 4 Bevacizumab 4 Aminolevulinic Acid 4 palbociclib 3 methyl 5-aminolevulinate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00006200 2005-06-24

Thalidomide and Dacarbazine for Metastatic Melanoma

National Center for Research Resources (NCRR)

Phase 2 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡